MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2023

Jun 18, 2023

==> picture [117 x 45] intentionally omitted <==

ASX Announcement

MITHRA ANNOUNCES SALE OF MAYNE PHARMA SHARES

19 June 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX:MYX) confirms that Estetra SRL, a subsidiary of Mithra Pharmaceuticals, SA ( Mithra ) (Euronext Brussels: MITRA) recently sold 4,221,815 Mayne Pharma shares, as announced by Mithra on 16 June 2023.

A copy of Mithra’s announcement is attached to this release.

As per the announcement, Mithra notes that their holding in Mayne Pharma has reduced to 4.96%. Further, the release also states that Mithra does not currently intend to sell its remaining stake.

Mayne Pharma continues to hold an exclusive license to commercialise NEXTSTELLIS ® , Mithra’s novel combined oral contraceptive, in both the United States and Australia. Mayne Pharma looks forward to continuing our strong collaboration with Mithra for the successful commercialisation of NEXTSTELLIS ® .

For further information contact:

Australia: US: Craig Haskins Lisa M. Wilson +61 421 029 843 +917 543 9932 ir@maynepharma.com ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

==> picture [227 x 54] intentionally omitted <==

==> picture [126 x 130] intentionally omitted <==

16 June 2023

REGULATED INFORMATION/ PRIVILEGE INFORMATION

==> picture [171 x 74] intentionally omitted <==

Mithra Announces Sale of Shares in Mayne Pharma

• Sells 4,221,815 shares to reduce stake in Mayne Pharma to 4.96%

• Shares acquired as part of agreement on US commercialization of Estelle®

• Natural point to monetize investment, following authorization and launch in US

• Remains major shareholder in Mayne Pharma and strong collaboration continues

Liege, Belgium, 16June 2023 – 8:50 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the sale of 4,221,815 shares in Mayne Pharma Group Limited (ASX: MYX) at a price of A$3.86 per share, in line with Mayne Pharma’s last close (ie 0% discount). The settlement is expected to take place at T+2 business days.

Mithra continues to hold 4,221,816 shares in Mayne Pharma, a leading Women’s Health player in oral contraceptives in the US, and its stake now corresponds to 4.96% of the outstanding shares in Mayne Pharma listed on ASX, from the previous 9.93%. The Company has no intention to divest its current participation in Mayne Pharma.

Mithra acquired the shares in Mayne Pharma as part of a License and Supply Agreement for an exclusive license to commercialize Estelle®, Mithra’s novel combined oral contraceptive, in the US, which was concluded in 2019. Under the terms of the agreement, Mithra had a seat on the Mayne Pharma Board of Directors and was involved in the steering committee for the US launch of Estelle®, under the trademark Nextstellis®.

David Horn Solomon, Chief Executive Officer of Mithra , commented: “As these shares were received as part of payment for US marketing rights to Estelle, it is time that we monetize them to provide cash for Mithra’s operations. We have made good progress in partnership with Mayne Pharma, including achieving US marketing authorization and the commercial launch. With the recent start of a direct-toconsumer campaign of television advertising, we are optimistic that our US marketing partner will increase Nextstellis® sales. We remain a major shareholder in Mayne Pharma and look forward to continuing our strong collaboration.”

There was a lockup period on the shares until market authorization for Estelle® was achieved in May 2021. A Mayne Pharma share buyback program, announced in May 2023, had raised the possibility of Mithra’s shareholding breaching a 9.9% threshold which it had agreed not to go above in the 2019 Master Share Purchase Agreement. Mithra does not currently intend to sell its remaining stake in Mayne Pharma.

For more information, please contact:

Mithra Pharmaceuticals SA Investor & media relations David Horn Solomon Chris Maggos Chief Executive Officer Cohesion Bureau investorrelations@mithra.com

investors.mithra.com • 1

16 June 2023

REGULATED INFORMATION/ PRIVILEGE INFORMATION

chris.maggos@cohesionbureau.com +41 79 367 6254

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle[®] , Mithra is now focusing on its second product Donesta[®] , the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE[®] , and DONESTA[®] are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media : Linkedin • Twitter • Facebook

investors.mithra.com • 2